EUVIMEDEUVIMED entdecken
Crossref

In Brief: Semaglutide (Wegovy) for Weight Loss in Children

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1670d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy), which was approved by the FDA in 2021 for chronic weight management in adults,1 has now been approved for chronic weight management in children ≥12 years old with an initial BMI in the ≥95th percentile for age and sex.Semaglutide is also available as Ozempic and Rybelsus for treatment of type 2 diabetes in adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsDiabetes Mellitus, Type 2HumansChildObesityWeight LossGlucagon-Like PeptidesPhentermineSemaglutide

Stichwörter der Autor:innen

BydureonQsymiaSaxendaWegovyXenicaladverse effectsdosagedrug interactionsefficacyliraglutidemetforminorlistatphenterminesafetysemaglutide

Substanzen

Glucagon-Like PeptidesAnti-Obesity AgentsPhentermineSemaglutide

Zitieren

APA

(2023). In Brief: Semaglutide (Wegovy) for Weight Loss in Children. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670d

Vancouver

In Brief: Semaglutide (Wegovy) for Weight Loss in Children. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670d

BibTeX
@article{euvimed2023,
  title = {In Brief: Semaglutide (Wegovy) for Weight Loss in Children},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1670d}
}
Kostenlos starten →